Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors

被引：11
|
作者：
Sobecki-Rausch, Janelle [1 ]
Barroilhet, Lisa [1 ]
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, Div Gynecol Oncol, 600 Highland Ave, Madison, WI 53792 USA
来源：
CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2019年 / 20卷 / 11期
关键词：
Anti-PD-1; treatment; Endometrial cancer; Microsatellite instability; Mismatch repair deficiency; Pembrolizumab; IMMUNE CHECKPOINT INHIBITORS; LYNCH SYNDROME; OPEN-LABEL; PEMBROLIZUMAB; SAFETY;
D O I：
10.1007/s11864-019-0679-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Among gynecologic malignancies, mismatch repair-deficient endometrial cancers show the greatest response to anti-programmed cell death-1 (PD-1) antibodies, such as pembrolizumab. Routine immunohistochemical (IHC) and molecular testing should be performed on all endometrial cancers at the time of diagnosis in order to identify endometrial cancers with mismatch repair deficiency that may show improved response to anti-PD-1 therapy in the progressive or metastatic setting. Institutional effort to enroll patients in clinical trials investigating the use of immune checkpoint inhibitors in endometrial cancer should be prioritized.
引用
收藏
页数：10
相关论文
共 50 条
  • [21] Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
    Takuma Imakita
    Kohei Fujita
    Takanori Ito
    Zentaro Saito
    Issei Oi
    Osamu Kanai
    Hiromasa Tachibana
    Satoru Sawai
    Tadashi Mio
    Discover Oncology, 14
  • [22] Programmed Cell Death-Ligand 1 Expression in Microsatellite Instability-High Gastric Carcinomas
    Cho, Junhun
    Chang, Young Hwan
    Bae, Hyunsik
    Kim, Kyoung-Mee
    LABORATORY INVESTIGATION, 2017, 97 : 165A - 166A
  • [23] Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
    Imakita, Takuma
    Fujita, Kohei
    Ito, Takanori
    Saito, Zentaro
    Oi, Issei
    Kanai, Osamu
    Tachibana, Hiromasa
    Sawai, Satoru
    Mio, Tadashi
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [24] Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
    Lee, Yong Jun
    Lee, Jii Bum
    Ha, Sang-Jun
    Kim, Hye Ryun
    MOLECULES AND CELLS, 2021, 44 (05) : 363 - 373
  • [25] Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum
    Salomon, G.
    Maza, A.
    Boulinguez, S.
    Paul, C.
    Lamant, L.
    Tournier, E.
    Mazereeuw-Hautier, J.
    Meyer, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) : 1199 - 1203
  • [26] Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
    Bernard-Tessier, A.
    Baldini, C.
    Martin, Patricia
    Champiat, Stephane
    Hollebecque, Antoine
    Postel-Vinay, Sophie
    Varga, Andrea
    Bahleda, Rastilav
    Gazzah, Anas
    Michot, Jean-Marie
    Ribrag, Vincent
    Armand, Jean-Pierre
    Marabelle, Aurelien
    Soria, Jean-Charles
    Massard, C.
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 160 - 164
  • [27] Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
    Weber, Jeffrey S.
    Postow, Michael
    Lao, Christopher D.
    Schadendorf, Dirk
    ONCOLOGIST, 2016, 21 (10): : 1230 - 1240
  • [28] Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma
    Guo, Lei
    Li, Hongbo
    Fan, Tianli
    Ma, Yanli
    Wang, Lili
    LIFE SCIENCES, 2021, 279
  • [29] Adverse events associated with "Anti-programmed death-1" therapy for patients with melanoma
    De Francesco, Adele Emanuela
    De Fina, Mariarosanna
    Zito, Maria Cristina
    Bisceglia, Maria Dezia
    Esposito, Stefania
    Fersini, Giuseppina
    JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
  • [30] Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis
    Chakravarti, Nitin
    Prieto, Victor G.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (06) : 743 - 751
12345